How does methotrexate affect young patients growth rates?

Why methotrexate can slow a child’s growth
Methotrexate blocks folate metabolism, which is needed for DNA synthesis in rapidly dividing cells. In growing children, this interference can reduce the proliferation of chondrocytes in growth plates and bone marrow, leading to slower height gains during periods of treatment.[1]

Is the impact dose‑dependent?
Higher cumulative doses and longer treatment courses are associated with greater reductions in growth velocity. Children receiving weekly doses for juvenile idiopathic arthritis or systemic lupus erythematosus may see a more noticeable effect than those on lower, intermittent regimens.[1]

Can children catch up after stopping methotrexate?
In many cases, growth slows while the drug is in use but resumes once therapy ends, especially if treatment was not prolonged or if the cumulative dose was moderate. The timing of catch‑up varies, and some children may never fully regain the growth velocity lost during therapy.[1]

What do clinicians monitor?
Pediatric rheumatologists routinely plot height and weight on standardized growth charts, checking for a deceleration in percentile tracking. Bone age x‑rays and serum folate levels are also reviewed to gauge bone maturation and nutritional status.[1]

Does the drug affect bone density?
Methotrexate can reduce bone mineral density in children, particularly when combined with corticosteroids. This loss of density may further impair linear growth and increase fracture risk.[1]

Can growth spurts still occur?
Pubertal growth spurts can still happen, but the overall height gain may be limited if methotrexate is taken throughout adolescence. Adjusting the dose or adding folinic acid rescue can help mitigate the effect while maintaining disease control.[1]

What alternatives exist for growth‑concerned patients?
In cases where growth retardation is significant, clinicians may consider biologic agents (e.g., adalimumab, etanercept) that do not interfere with cell division, though these have their own safety profiles.[1]

How to balance disease control with growth preservation?
Shared decision‑making is key: patients and families weigh the benefits of disease remission against the potential for slowed growth. Regular growth assessments and dose adjustments can help maintain both health and height goals.[1]

Sources
[1] https://www.drugpatentwatch.com/​